GlassScriptPhysician profile
Debra B Curtis
NPI 1083729065
$6,347.86
in general payments reported to CMS, 2019-2025
35 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $732 · 2021: $655 · 2022: $1,257 · 2023: $1,319 · 2024: $1,129 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,324 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,324.08 |
| Education | $162.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,085.03 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,041.79 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $766.48 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $705.20 | 2023-2025 | Veozah |
| Pfizer INC. | $256.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.71 | 2020-2025 | Jardiance |
| Abbott Laboratories | $228.38 | 2020-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $207.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $191.59 | 2019-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $170.93 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $165.85 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $153.05 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.41 | 2019-2024 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $123.74 | 2022-2023 | Quviviq |
| Horizon Therapeutics Plc | $121.55 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $96.84 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $77.74 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Amgen INC. | $76.38 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Janssen Pharmaceuticals, INC | $65.71 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.71 | 2025 | |
| Eisai INC. | $56.05 | 2020 | |
| Allergan, INC. | $45.03 | 2020 | |
| Genzyme Corporation | $28.09 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $27.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.79 | 2020 | |
| Kaleo, INC. | $22.76 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $21.93 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $18.68 | 2025 | Neffy |
| Daiichi Sankyo INC. | $18.32 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $17.74 | 2024 | |
| Lundbeck LLC | $16.24 | 2024 | Vyepti |
| Endo Pharmaceuticals INC. | $15.97 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.73 | 2019 | |
| Phadia US INC. | $14.26 | 2023 | Immunocap |
| Hikma Pharmaceuticals USA | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.